NCPA Awards recognize 8 independent pharmacies
The National Community Pharmacy Association has honored eight independent pharmacies with its inaugural NCPA Innovation Center Excellence Awards. The Alexandria, Va.-based organization said it created the awards, which are partly sponsored by CoverMyMeds, to recognize pharmacies that have enhanced their spaces to better serve patients and communities.
NCPA said that it received more than 70 submissions for pharmacies seeking recognition in such categories as Best External Remodel, Best Advertising/Marketing Promotion, Best End-Cap, Best Public Event and Best Customer Convenience Improvement.
“The NICE Awards spotlight the best of community pharmacy branding and marketing – the innovations and redesigns that have made promotions more effective and patients’ experiences more rewarding,” said Kurt Proctor, PhD, president of the NCPA Innovation Center. “Small businesses have to be nimble in the competitive marketplace and this year’s eight recipients are a testament to the power of successful reinvention. Congratulations to all of the eight pharmacy honorees on this well-deserved recognition.”
The winners were:
- Best External remodel – Centralia Pharmacy in Centralia, Wash.
- Best Internal Remodel – Skywalk Pharmacy in New Berlin, Wis.
- Best End-Cap – Stephens Pharmacy and Northeast Med-Equip in Honesdale, Pa.
- Best Exterior Sign – Davies Drugs in Canton, Ohio
- Best Advertising/Marketing Promotion – AXIS Pharmacy Northwest in Mountlake Terrace, Wash.
- Best Social Media Campaign – Love Oak Pharmacy in Eastland, Texas
- Best Public Event – Petricone’s Torrington Pharmacy in Torrington, Conn.
- Best Customer Convenience Improvement – Good Day Pharmacy in Loveland, Colo.
The winners were selected by three judges — Pharmacy Development Services president Dan Benamoz, Hamacher Resource Group vice president of strategic relations Dave Wendland and Pharm Fresh Media president Liz Tiefenthaler.
Mylan to launch 2 HIV treatments
Mylan will soon be bringing its recently approved HIV medications Symfi Lo and Cimduo to market. The company on Friday said Symfi Lo would become available in the coming weeks, with Cimduo’s launch anticipated in the second quarter. Mylan said that the launches are aimed at reducing the cost of HIV treatments, which is more than $20 billion annually, according to IQVIA data.
“As the world’s largest supplier of antiretrovirals by volume, Mylan is deeply committed to expanding access to treatment for people living with HIV,” said Mylan CEO Heather Bresch. “For a decade, we have helped transform the level of access to high-quality, affordable HIV medications in developing countries. We are excited to bring that same passion to the U.S. with the upcoming launches of Symfi Lo and Cimduo and help deliver significant savings to the healthcare system.”
Symfi Lo (efavirenz, lamivudine 400 mg and tenofovir disoproxil fumarate 300 mg) is a once-daily single-tablet antiretroviral regimen indicated as a complete treatment for HIV-1 in adults and children weighing at least 35 kg. Cimduo (lamivudine 300 mg and tenofovir disoproxil fumarate 300 mg) is a once-daily combination of two nucleoside reverse transcriptase inhibitors that is indicated to be used in combination with other antiretroviral medications to treat HIV.
Mylan said that Symfi Lo’s efavirenz dose is one-third less than the dose originally approved in 1998, and the product was given tentative approval from the Food and Drug Administration in February under the U.S. President’s Emergency Plan for AIDS Relief program. The company dispensed the drug to more than 1 million patients worldwide last year, it said.
“Symfi Lo and Cimduo bring to the U.S. the innovations Mylan has pioneered in the delivery and dosage forms of ARVs used by millions of patients in high-burden countries around the world. We are proud of our continued investments in R&D and manufacturing for ARVs, and we are excited to extend the value of these to Americans living with HIV,” said Mylan President Rajiv Malik. “In particular, we believe the option to take a lower dose of efavirenz in a single-tablet regimen with Symfi Lo will be a welcome addition for patients and providers.”
The company said that it would discount Symfi Lo’s list price, and it would offer Cimduo as a significantly discounted list price compared with other similar treatments.
Amneal intros generic Tamiflu for oral suspension
Amneal Pharmaceuticals has introduced its generic Tamiflu for oral suspension (oseltamivir phosphate, 6 mg/ml). The Bridgewater, N.J.-based company’s product is a powder finished dosage that is packaged in bottles with 60 ml of usable volume following constitution.
Amneal’s generic Tamiflu for oral suspension joins generic Tamiflu capsules that it launched in July 2017.
“Approval and launch of this liquid form should be of great assistance to patients and caregivers,” Amneal executive vice president of commercial operations Andy Boyer said. “With a severe flu season upon us, our product should be able to help provide relief to thousands of patients. We are pleased to provide this liquid dosage form to patients, particularly the elderly and young who are unable to use an oral solid form.”
The drug is indicated to prevent the flu and as a treatment in patients who have been symptomatic for less than 48 hours. The drug’s market size was roughly $956 million for the 12 months ended December 2017, according to IQVIA data.